BRPI0920687A2 - Composto,composição farmacêutica, e, métodos para inibir a formação, deposição, acúmulo, ou persistência de abeta amilóide ou agregados de alfa-sinucleína, para tratar uma doença beta-amilóide ou uma sinucleinopatia em um mamífero que sofre disto, para melhorar o desempenho motor em um mamífero que sofre de uma sinucleinopatia, e para suspender a progressão de déficits motores em um mamífero que sofre de mal de parkinson - Google Patents

Composto,composição farmacêutica, e, métodos para inibir a formação, deposição, acúmulo, ou persistência de abeta amilóide ou agregados de alfa-sinucleína, para tratar uma doença beta-amilóide ou uma sinucleinopatia em um mamífero que sofre disto, para melhorar o desempenho motor em um mamífero que sofre de uma sinucleinopatia, e para suspender a progressão de déficits motores em um mamífero que sofre de mal de parkinson

Info

Publication number
BRPI0920687A2
BRPI0920687A2 BRPI0920687-6A BRPI0920687A BRPI0920687A2 BR PI0920687 A2 BRPI0920687 A2 BR PI0920687A2 BR PI0920687 A BRPI0920687 A BR PI0920687A BR PI0920687 A2 BRPI0920687 A2 BR PI0920687A2
Authority
BR
Brazil
Prior art keywords
suffering
mammal
synucleinopathy
disease
amyloid
Prior art date
Application number
BRPI0920687-6A
Other languages
English (en)
Inventor
Luke A Esposito
F Michael Hudson
Thomas Lake
Joel Cummings
Manfred Weigele
Allan D Snow
Lesley Larsen
Original Assignee
Proteotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteotech Inc filed Critical Proteotech Inc
Publication of BRPI0920687A2 publication Critical patent/BRPI0920687A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/16—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/10—Polyhydroxy benzenes; Alkylated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0920687-6A 2008-10-03 2009-06-26 Composto,composição farmacêutica, e, métodos para inibir a formação, deposição, acúmulo, ou persistência de abeta amilóide ou agregados de alfa-sinucleína, para tratar uma doença beta-amilóide ou uma sinucleinopatia em um mamífero que sofre disto, para melhorar o desempenho motor em um mamífero que sofre de uma sinucleinopatia, e para suspender a progressão de déficits motores em um mamífero que sofre de mal de parkinson BRPI0920687A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/244,968 US8829198B2 (en) 2007-10-31 2008-10-03 Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
PCT/US2009/048855 WO2010039308A1 (en) 2008-10-03 2009-06-26 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF β-AMYLOID DISEASES AND SYNUCLEINOPATHIES

Publications (1)

Publication Number Publication Date
BRPI0920687A2 true BRPI0920687A2 (pt) 2015-08-18

Family

ID=40583657

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920687-6A BRPI0920687A2 (pt) 2008-10-03 2009-06-26 Composto,composição farmacêutica, e, métodos para inibir a formação, deposição, acúmulo, ou persistência de abeta amilóide ou agregados de alfa-sinucleína, para tratar uma doença beta-amilóide ou uma sinucleinopatia em um mamífero que sofre disto, para melhorar o desempenho motor em um mamífero que sofre de uma sinucleinopatia, e para suspender a progressão de déficits motores em um mamífero que sofre de mal de parkinson

Country Status (29)

Country Link
US (2) US8829198B2 (pt)
EP (1) EP2328417B1 (pt)
JP (1) JP5431485B2 (pt)
KR (1) KR20110086549A (pt)
CN (1) CN102170787B (pt)
AU (2) AU2009300298A1 (pt)
BR (1) BRPI0920687A2 (pt)
CA (1) CA2735120C (pt)
CL (1) CL2011000739A1 (pt)
CO (1) CO6382089A2 (pt)
CY (1) CY1115725T1 (pt)
DK (1) DK2328417T3 (pt)
ES (1) ES2519140T3 (pt)
HR (1) HRP20140967T1 (pt)
IL (1) IL211313A (pt)
MA (1) MA32686B1 (pt)
ME (1) ME02017B (pt)
MX (1) MX2011002830A (pt)
MY (1) MY156302A (pt)
NZ (1) NZ591504A (pt)
PE (1) PE20110930A1 (pt)
PL (1) PL2328417T3 (pt)
PT (1) PT2328417E (pt)
RS (1) RS53613B1 (pt)
RU (1) RU2501792C2 (pt)
SI (1) SI2328417T1 (pt)
UA (1) UA101393C2 (pt)
WO (1) WO2010039308A1 (pt)
ZA (1) ZA201101278B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
ES2907862T3 (es) 2009-12-10 2022-04-26 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
EP3920921A4 (en) * 2019-02-07 2022-11-02 Alsatech, Inc. POLYVALENT EMOXYPIN DERIVATIVES
EP4368184A3 (en) * 2019-11-19 2024-07-31 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
CN114573570B (zh) * 2022-02-21 2023-05-30 中山大学 一类α-突触核蛋白靶向化合物及其制备方法和应用
CN115650957B (zh) * 2022-09-16 2023-12-15 中山大学 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用
WO2025053670A1 (ko) * 2023-09-08 2025-03-13 주식회사 테라노큐어 바닐릭산 유도체 화합물, 이를 포함하는 알츠하이머 치료제 조성물 및 신경염증 치료제 조성물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5387681A (en) * 1992-08-19 1995-02-07 Eli Lilly And Company Synthesis of bicyclic aromatic sulfonic acids sulfonyl chlorides and sulfonamides
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) * 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) * 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) * 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) * 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
JP2000508339A (ja) * 1996-10-01 2000-07-04 シーマ・ラブス・インコーポレイテッド 味隠蔽マイクロカプセル組成物及び製造方法
US6131570A (en) * 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6288061B1 (en) * 1997-12-26 2001-09-11 Welfide Corporation Imidazole derivatives
JP2004067510A (ja) * 1997-12-26 2004-03-04 Mitsubishi Pharma Corp 新規イミダゾール誘導体
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) * 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2003053986A1 (en) * 2001-12-21 2003-07-03 Ciba Specialty Chemicals Holding Inc. Use of metal complex compounds as oxidation catalysts
US20070276034A1 (en) * 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
WO2003101927A1 (en) * 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2004033432A1 (ja) * 2002-10-09 2004-04-22 Ssp Co., Ltd. 抗真菌活性を有する新規ピラゾール化合物
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US8916598B2 (en) * 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
US8193389B2 (en) * 2004-03-11 2012-06-05 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
CA2597332A1 (en) * 2005-02-10 2006-08-17 Novartis Ag Methods for improving drug disposition
EP1879548A2 (en) 2005-05-13 2008-01-23 Ciba Specialty Chemicals Holding Inc. Process for coloring keratin fibers comprising metal complexes
WO2007051773A1 (en) * 2005-11-01 2007-05-10 Novartis Ag Method of scintigraphy
BRPI0715123A2 (pt) 2006-08-04 2013-06-04 Novartis Ag tratamento de disfunÇço endàcrina usando quelantes de ferro
CA2685043A1 (en) 2007-05-14 2008-11-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
EP1994930A1 (en) 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
EP2687513B1 (en) 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases

Also Published As

Publication number Publication date
CN102170787A (zh) 2011-08-31
KR20110086549A (ko) 2011-07-28
SI2328417T1 (sl) 2014-12-31
PE20110930A1 (es) 2012-01-20
ME02017B (me) 2015-05-20
ES2519140T3 (es) 2014-11-06
RU2011117544A (ru) 2012-11-10
CN102170787B (zh) 2014-11-12
DK2328417T3 (da) 2014-11-03
JP2012504617A (ja) 2012-02-23
ZA201101278B (en) 2012-02-29
WO2010039308A1 (en) 2010-04-08
JP5431485B2 (ja) 2014-03-05
CA2735120C (en) 2014-07-22
EP2328417B1 (en) 2014-08-13
RU2501792C2 (ru) 2013-12-20
US20090111863A1 (en) 2009-04-30
MY156302A (en) 2016-01-29
US8829198B2 (en) 2014-09-09
US20120252858A1 (en) 2012-10-04
MA32686B1 (fr) 2011-10-02
AU2016201693A1 (en) 2016-04-07
AU2009300298A1 (en) 2010-04-08
HRP20140967T1 (hr) 2014-12-05
CL2011000739A1 (es) 2011-09-23
CO6382089A2 (es) 2012-02-15
PL2328417T3 (pl) 2015-02-27
EP2328417A4 (en) 2012-06-27
EP2328417A1 (en) 2011-06-08
US8592476B2 (en) 2013-11-26
UA101393C2 (ru) 2013-03-25
PT2328417E (pt) 2014-10-16
NZ591504A (en) 2012-11-30
IL211313A0 (en) 2011-04-28
CA2735120A1 (en) 2010-04-08
IL211313A (en) 2013-12-31
MX2011002830A (es) 2011-06-24
CY1115725T1 (el) 2017-01-25
RS53613B1 (sr) 2015-04-30

Similar Documents

Publication Publication Date Title
BRPI0920687A2 (pt) Composto,composição farmacêutica, e, métodos para inibir a formação, deposição, acúmulo, ou persistência de abeta amilóide ou agregados de alfa-sinucleína, para tratar uma doença beta-amilóide ou uma sinucleinopatia em um mamífero que sofre disto, para melhorar o desempenho motor em um mamífero que sofre de uma sinucleinopatia, e para suspender a progressão de déficits motores em um mamífero que sofre de mal de parkinson
LTPA2019504I1 (lt) Pagerintos TM nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
CY1122278T1 (el) Αντι il-36r αντισωματα
EP2148691A4 (en) LOCAL COMPLEMENTAL INHIBITION FOR THE TREATMENT OF COMPLEMENT-MEDIATED DISEASES
FR23C1002I2 (fr) 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse
BRPI0918194A2 (pt) ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BR112014016287A2 (pt) composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma
EP2119477A4 (en) COMPOSITION FOR THE TREATMENT OF XEROSTOMY OR DRY MOUTH
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
BRPI0917138A2 (pt) composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EP2790668A4 (en) BACTERIALLY DERIVED, INTACT MINICELLS TO DELIVER THERAPEUTIC AGENTS TO BRAIN TUMORS
BRPI1005153A2 (pt) composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
EP2884994A4 (en) COMPOSITION FOR THE TREATMENT OF HYPERLIPIDEMIA WITH AN OXYNTOMODULIN DERIVATIVE
EP2334176A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF NERVE DISEASES
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
WO2014160871A8 (en) Methods and agents for treating alzheimer's disease
BR112014009866A2 (pt) formulações de anticorpos e métodos
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
EP2344443A4 (en) PROCESS FOR PREPARING 60 OR HIGHER PERCENT CIS-DI- (C4-C20-) ALKYL-CYCLOHEXAN-1,4-DICARBOXYLATE
EP2571360A4 (en) METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
EP2171592A4 (en) PARALLELIZATION OF SEQUENCIAL FRAMEWORK CONDITIONS USING TRANSACTIONS
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]